| | Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudicationReceived 2 August 2006; accepted 1 September 2006. published online 29 November 2006. BackgroundObesity is recognized as an independent predictor of coronary artery disease; however, its importance in peripheral arterial disease is less clear. The aim of this study was to assess the association between obesity and the severity and outcome of intermittent claudication. MethodsThis study was a prospective cohort study based at a tertiary referral center. Sixty patients with intermittent claudication selected for conservative treatment were assessed for obesity and metabolic syndrome by using the International Diabetes Federation definition. Other risk factors, including diabetes, hypertension, smoking history, serum lipids, adipocytokines, and C-reactive protein, were measured by clinical and blood assessment. Obesity and metabolic syndrome were related to the severity of peripheral arterial disease, defined by ankle-brachial pressure index and graded treadmill measured maximum walking distance (MWD) and initial claudication distance, by using multiple linear regression analysis allowing for traditional atherosclerotic risk factors. Patients were followed up for 24 months, and combined outcome was reported in terms of death, cardiovascular events, or requirement for revascularization. The effect of obesity and metabolic syndrome on outcome was investigated by using Kaplan-Meier and Cox proportional hazard analysis. ResultsObesity and serum adiponectin were independently associated with the severity of peripheral arterial disease measured by ankle-brachial pressure index (P = .03 and .001), initial claudication distance (P = .009 and .03), and MWD (P = .001 and .04). Metabolic syndrome was independently associated only with MWD (P = .02). By 24 months, outcome events occurred in 37% ± 7% and 43% ± 9% of patients with metabolic syndrome or obesity, respectively, compared with 0% and 11% ± 6% of those without these diagnoses. Waist circumference independently predicted the likelihood of outcome events (relative risk, 1.16; 95% confidence interval, 1.08-1.26; P < .001). ConclusionsThese findings, if confirmed in other cohorts, suggest the importance of treating obesity in patients with intermittent claudication. Serum adiponectin concentrations may be an important guide to the efficacy of treatment in patients with intermittent claudication and obesity. The increasing incidence of obesity has focused research on this modifiable risk factor for cardiovascular disease.1, 2 There is particular interest in a constellation of risk factors associated with obesity, known as the metabolic syndrome, that are thought to result from insulin resistance.3 Some, but not all, studies suggest an independent association between obesity or metabolic syndrome and coronary events.4, 5, 6, 7 Because peripheral arterial disease is common in patients with diabetes mellitus, it is not surprising that metabolic syndrome has been particularly linked with lower limb artery disease.8, 9 In animal models, obesity has been specifically linked with impaired limb blood flow.10 The interpretation of studies of obesity and metabolic syndrome is complicated by the use of a number of different definitions and evidence; depending on which criteria are used, the outcome varies.4, 11 Two large population studies found no association between body mass index and symptomatic or asymptomatic lower limb artery disease.12, 13 In one of these studies in which 708 men were examined, a waist-hip ratio above the median was independently associated with peripheral arterial disease at an odds ratio of 1.7.13 These findings support studies of coronary artery disease indicating that abdominal girth is a much more important risk factor for vascular disease than body mass index.4 It has been suggested that screening patients with demonstrated vascular disease for obesity and metabolic syndrome may identify high-risk subgroups to direct intensive treatment.14 Few studies have examined the effect of obesity and metabolic syndrome on the outcome in patients with existing peripheral arterial disease. In this study, we assessed the prevalence of metabolic syndrome and obesity in a cohort of patients with intermittent claudication. We used girth measurements and the International Diabetes Federation definition of metabolic syndrome.15 We assessed two hypotheses: (1) that obesity and/or metabolic syndrome is associated with more severe intermittent claudication and (2) that obesity and/or metabolic syndrome is associated with a poorer prognosis during follow-up, as evidenced by more frequent cardiovascular or revascularization events. Methods  Patients Approval for this study was provided by the ethics committees of the Townsville Hospital, the Mater Hospital, and James Cook University. In this prospective study, we consecutively assessed patients with symptomatic peripheral arterial disease referred to the Townsville Hospital. Patients were initially assessed by a consultant vascular surgeon to identify those with intermittent claudication secondary to peripheral arterial disease. Intermittent claudication was defined by an appropriate history, a positive Edinburgh claudication questionnaire response, and an ankle-brachial pressure index (ABPI) less than 0.9.16 Patients with critical ischemia (rest pain or tissue loss) or nonvascular symptoms were excluded. Because only patients with lifestyle-limiting intermittent claudication are referred to the vascular clinic, all patients underwent a computed tomographic angiogram to assess whether endovascular therapies were feasible. Because the second aim of this study was to assess the association between obesity and cardiovascular or revascularization events, patients selected for endovascular or open vascular surgery were excluded. The remaining patients who had intermittent claudication and were selected for medical treatment were eligible for the study. Medical treatment consisted of advice on exercise, smoking cessation, and control of cardiovascular risk factors under the supervision of a cardiovascular physician. As a result, 10 and 6 patients were started on treatment for diabetes and dyslipidemia, respectively. The patients had detailed further assessment, including recording of medical history, examination, blood, and imaging findings. Clinical definitions Hypertension was defined by systolic blood pressure of 130 mm Hg or higher, diastolic blood pressure of 85 mm Hg or higher, or previously diagnosed and treated high blood pressure.15 Diabetes was defined by a fasting blood glucose of 7.0 mmol/L or higher or, for patients with fasting glucose between 6.1 and 6.9 mmol/L, a positive oral glucose tolerance test.17 Cigarette smoking classification was based on a history as current smokers (smoked within the last month), ex-smokers (given up for more than 1 month), and never-smokers. Ischemic heart disease was defined by a history of myocardial infarction, angina, or coronary revascularization. Cerebrovascular disease was defined by a history of stroke, transient ischemic attack, or cerebral revascularization. Dyslipidemia was defined according to the European Joint Society of Cardiologists criteria as total cholesterol of 4.5 mmol/L or higher, low-density lipoprotein 2.5 mmol/L or higher, or current lipid-lowering treatment.18 Blood analysis Blood was collected after an overnight fast and assessed for full blood count, urea and electrolytes, glucose, cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein, and C-reactive protein (CRP), as previously described.19 Blood glucose was measured by the glucose oxidase method, lipids by automated enzymatic methods, and CRP by particle-enhanced turbidimetry (Roche Diagnostics, Basel, Switzerland).19 Serum was stored at −80°C for later batch assessment of adiponectin, leptin, and resistin concentrations by using enzyme-linked immunosorbent assay (R&D Systems). Intra-assay and interassay coefficients of variation for these assays are between 3% and 6% in our laboratory. Assessment of obesity and metabolic syndrome On entry into the study, patients’ weight, height, and waist and hip circumference were measured in accordance with guidelines of the International Society for the Advancement of Kinanthropometry.20 The percentage body fat was measured by bioelectrical impedance scales (TBF 521; Tanita Corporation of America, Arlington Heights, Ill).21 Body mass index was calculated as weight in kilograms divided by height in meters squared. Obesity and metabolic syndrome were defined by using the International Diabetes Federation classification, which uses varying waist circumferences for different populations. In our study, because patients were of European origin, we defined obesity as a waist circumference of 94 cm or greater for men and 80 cm or greater in women.15 Metabolic syndrome was diagnosed when obesity was present in addition to two of the following: fasting triglycerides 1.7 mmol/L or more or specific treatment to decrease triglycerides; HDL less than 1.03 mmol/L in men or less than 1.29 mmol/L in women or specific treatment to increase HDL; hypertension; fasting glucose 5.6 mmol/L or more; or treated diabetes mellitus.15 Objective assessment of peripheral vascular disease A consultant vascular surgeon documented the presence of peripheral pulses and reviewed the computed tomographic angiogram. The site of arterial occlusions or stenoses greater than 50% was documented from the angiogram, and the peripheral vascular disease was recorded as aortoiliac, infrainguinal, or combined. ABPI measurements were performed by a qualified sonographer. Participants rested supine for 10 minutes before measurement of the ABPI. The ABPI was calculated by measuring the systolic blood pressure at the ankle (taking the highest of either the dorsalis pedis or posterior tibial arteries) with a handheld bidirectional Doppler scanner (MD6; D.E. Hokanson Inc., Bellevue, Wash, USA) and then dividing that value by the systolic blood pressure in the brachial artery.22 Larger sphygmomanometer cuffs were used in obese patients. Treadmill assessment was also performed. Patients were initially familiarized with walking on the treadmill by a practice session. Maximum walking distance (MWD) and initial claudication distance (ICD) were subsequently measured during a graded treadmill test.23 The treadmill test commenced at 3.2 km/h and an incline of 0%, and the incline was increased by 2% every 2 minutes until voluntary exhaustion or maximal claudication pain.24 Follow-up Patients were followed up at 3, 6, 12, 18, and 24 months. Notes were flagged to identify events outside the review visits. The following end points were noted: death, myocardial infarction, stroke, and coronary or peripheral revascularization. Statistical analysis Data were recorded in a spreadsheet (Excel; Microsoft, Redmond, Wash) and transferred to a statistical package for analysis (SPSS 12.0; SPSS Inc, Chicago, Ill). Initially the relationships between waist circumference, waist-hip ratio, and circulating adipocytokines and ABPI, ICD, and MWD were assessed. To investigate the independent association of obesity and metabolic syndrome with the severity of intermittent claudication, multiple linear regression analysis was performed by using the dependent variables ABPI, ICD, or MWD and the covariants age, sex, smoking history, diabetes, hypertension, and dyslipidemia (the last three criteria were not included in metabolic syndrome analyses because these are part of the diagnostic criteria). The influence of obesity or metabolic syndrome on combined end points during follow-up was assessed with Kaplan-Meier analysis. Because all events occurred in patients with metabolic syndrome, we used a surrogate marker of obesity—ie, waist circumference—to perform a Cox proportional hazard analysis allowing for other determinants of cardiovascular events (age, sex, smoking, diabetes, hypertension, and dyslipidemia). Results Characteristics of patients in relation to obesity and metabolic syndrome Between June 2003 and June 2005, 60 patients were entered into the study, of whom 48 were defined as obese and 44 as having metabolic syndrome. The characteristics of patients in relation to whether they were obese or had metabolic syndrome are illustrated in Table I. Relationship between obesity or metabolic syndrome and severity of peripheral arterial disease Waist-hip ratio, but not waist circumference, was correlated with the severity of peripheral arterial disease as assessed by ABPI (r = 0.41; P = .001; Fig, a), but not by MWD (r = 0.18; P = .17) or ICD (r = 0.21; P = .10). The severity of peripheral arterial disease by all three different definitions was correlated with serum adiponectin concentrations (Fig, b-d). Allowing for other known determinants of atherosclerosis, obesity was independently associated with the severity of lower limb artery disease (Table II). Metabolic syndrome was associated with the severity of intermittent claudication as defined by MWD only (standardized coefficient = −0.343; P = .02), allowing for age, sex, and smoking history. The adipocytokines adiponectin and leptin were strongly associated with ABPI after adjustment for traditional cardiovascular risk factors (Table III). Serum adiponectin was also weakly independently associated with MWD (standardized coefficient = 0.277; P = .04) and ICD (standardized coefficient = 0.292; P = .03). Discussion The incidence of obesity is increasing, and there is now greater focus on this risk factor as a cause of coronary artery disease.1, 2, 3, 4, 5, 6 Lower limb artery disease is present in approximately 10% of the population over 60 years old, but in comparison with ischemic heart disease, it is poorly investigated.25 The importance of obesity in the development and progression of peripheral arterial disease has received relatively little attention. The recent American task force practice guidelines for the management of patients with peripheral arterial disease did not consider obesity as a treatable cause of lower limb artery disease.26 Some, but not all, studies have correlated obesity with the presence of lower limb artery disease, particularly when obesity is defined by abdominal girth measurements.7, 8, 9, 12, 13, 14, 27, 28 However, there are few investigations of how obesity affects the severity and outcome of lower limb artery disease. This study suggests the importance of obesity in predicting more severe lower limb artery disease and worse outcomes during follow-up in patients with intermittent claudication. Obesity independently predicted more severe intermittent claudication as assessed by ABPI, ICD, or MWD (Table II). Metabolic syndrome was associated only with MWD. The most important finding of this study was the poor outcome of patients with obesity or metabolic syndrome during intermediate-term follow-up. All the patients who had a cardiovascular event during follow-up had metabolic syndrome. Although as a result of this disparity it was not possible to include metabolic syndrome in a Cox proportional hazard analysis, we did assess the independent association between waist circumference and outcome events (Table IV). This analysis demonstrated an important association between larger waist circumference and increased outcome events. The correlation between serum adiponectin and all three measures of the severity of peripheral arterial disease suggests that this adipocytokine plays an important role in the poor prognosis associated with obesity in patients with lower limb ischemia (Fig). Both adiponectin and leptin were particularly associated with ABPI after adjustment for other cardiovascular risk factors. Serum adiponectin levels have been previously negatively correlated with coronary artery disease severity and progression.29, 30 Recently, Iwashima and colleagues31 reported an association between ABPI and serum adiponectin, although the investigators did not perform any functional tests of peripheral arterial disease. In animal models, adiponectin has been demonstrated to protect against the development of atherosclerosis.32 Several mechanisms have been suggested for this protective effect, including inhibition of thrombus formation and inflammation.33, 34, 35 Interpretation of this study must take into account several limitations. In developing this study, we believed that it was important to enter a homogenous group of patients—ie, patients with intermittent claudication planned to be treated conservatively. These tight entry criteria and the detailed number of investigations performed restricted the sample size. It will be important to confirm our findings in a larger cohort. We also plan to extend the follow-up for this group to assess whether the identified differences persist in the long term. We defined outcome in this study in terms of the clinical end points death, cardiovascular events, and revascularization. Most events during follow-up (10/15) were cardiovascular events. Five additional patients required revascularization for the development of critical ischemia (n = 2) or worsening intermittent claudication (n = 3). Decisions to perform revascularization in patients with intermittent claudication can be influenced by factors unrelated to the progression of peripheral arterial disease: eg, the type of arterial occlusive lesion. However, because most outcome events in this study were unrelated to revascularization for intermittent claudication, we do not believe that these factors altered our results. Ideally, other measures of outcome, such as health-related quality of life or objective assessments of peripheral arterial disease, would have been valuable to assess.36 In conclusion, the findings of this study suggest that obesity and metabolic syndrome predict poor outcome for patients with peripheral vascular disease. Interventions to target this problem in patients with lower limb artery disease are required. Author contributions Conception and design: JG, AL, WLS, FQ Analysis and interpretation: JG, AL Data collection: JG, AL, RGC, PC Writing the article: JG Critical revision of the article: JG, AL, RGC, PC, WLS, FQ Final approval of the article: JG, AL, RGC, PC, WLS, FQ Statistical analysis: JG Obtained funding: JG, AL, WLS Overall responsibility: JG We thank R. Kerr, K. Sangla, S. Glanville, and the staff of the Townsville Hospital Vascular Out-Patients for their help with this study. References 1. 1Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, et al. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol. 2004;24:1498–1502.
CrossRef
2. 2Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113:499–506.
CrossRef
3. 3Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006;29:625–630. MEDLINE 4. 4Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al.INTERHEART Study Investigators Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–1649. Abstract | Full Text |
Full-Text PDF (140 KB)
|
CrossRef
5. 5Rubinshtein R, Halon DA, Jaffe R, Shahla J, Lewis BS. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol. 2006;97:1277–1280. Abstract | Full Text |
Full-Text PDF (111 KB)
|
CrossRef
6. 6Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332:878–882. 7. 7Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, et al. Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care. 2006;29:1125–1127. MEDLINE |
CrossRef
8. 8Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FLThe SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2004;25:342–348.
CrossRef
9. 9Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96:655–658. Abstract | Full Text |
Full-Text PDF (119 KB)
|
CrossRef
10. 10Stepp DW, Pollock DM, Frisbee JC. Low-flow vascular remodeling in the metabolic syndrome X. Am J Physiol Heart Circ Physiol. 2004;286:H964–H970. MEDLINE 11. 11Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis. In press. 12. 12Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005;96:1579–1583. Abstract | Full Text |
Full-Text PDF (119 KB)
|
CrossRef
13. 13Planas A, Clara A, Pou JM, Vidal-Barraquer F, Gasol A, de Moner A, et al. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int J Obes Relat Metab Disord. 2001;25:1068–1070. MEDLINE |
CrossRef
14. 14Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FLSMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:363–369. MEDLINE 15. 15Alberti KG, Zimmet P, Shaw JIDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–1062. Full Text |
Full-Text PDF (63 KB)
|
CrossRef
16. 16Leng GC, Fowkes FG. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101–1109. MEDLINE |
CrossRef
17. 17American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl 1):S43–S48. 18. 18European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24:1601–1610.
CrossRef
19. 19Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636–1641.
CrossRef
20. 20Norton K, Whittingham N, Carter L, Kerr D, Gore C, Marfell-Jones M. Measurement techniques in anthropometry. In: Norton K, Olds T editor. Anthropometrica. Sydney: UNSW Press; 2000;p. 27–75. 21. 21Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab. 2005;90:1061–1067.
CrossRef
22. 22Golledge J, Ferguson K, Ellis M, Sabharwal T, Davies AH, Greenhalgh RM, et al. Outcome of femoropopliteal angioplasty. Ann Surg. 1999;229:146–153. MEDLINE |
CrossRef
23. 23TASC Working Group. Management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2000;19(Suppl A):S60. 24. 24Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23:402–408. MEDLINE 25. 25Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547–553.
CrossRef
26. 26ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Circulation. 2006;113:e463–e654.
CrossRef
27. 27Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48:312–314. MEDLINE 28. 28Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease (The Limburg PAOD Study. Peripheral Arterial Occlusive Disease). Scand J Prim Health Care. 1998;16:177–182. MEDLINE |
CrossRef
29. 29von Eynatten M, Schneider JG, Humpert PM, Kreuzer J, Kuecherer H, Katus HA, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol. 2006;47:2124–2126. Full Text |
Full-Text PDF (103 KB)
|
CrossRef
30. 30Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747–753.
CrossRef
31. 31Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis. 2006;188:384–390. Abstract | Full Text |
Full-Text PDF (205 KB)
|
CrossRef
32. 32Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–2770.
CrossRef
33. 33Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006;26:224–230.
CrossRef
34. 34Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–419.
CrossRef
35. 35Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–674.
CrossRef
36. 36Chong PF, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient-assessed condition-specific health outcome measure. J Vasc Surg. 2002;36:764–771. Abstract |
Full-Text PDF (158 KB)
|
CrossRef
a Vascular Biology Unit, James Cook University, Townsville, Queensland, Australia c Institute of Sport and Exercise Science, James Cook University, Townsville, Queensland, Australia b Townsville Hospital, Townsville, Queensland, Australia.  Reprint requests: Jonathan Golledge, MChir, MA, FRCS, FRACS, The Vascular Biology Unit, James Cook University, Townsville, Queensland 4811, Australia.
Supported by funding from the National Health and Medical Research Council (279408/379600), National Institutes of Health (R01 HL080010-01), and James Cook University. CME article PII: S0741-5214(06)01630-2 doi:10.1016/j.jvs.2006.09.006 © 2007 The Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. | |
|
FULL TEXT
01630-2/journalimage?img=PIIS0741521406016302.gr1.lrg.gif&fig=fig1&kwhquery=&issn=0741-5214&ishighres=false&allhighres=false&free=yes','journalimage');)
